Dr Sanjiv Agarwala reviews data for first-line immunotherapy with nivolumab plus relatlimab demonstrating significantly improved progression-free survival over monotherapy, and a high pathologic complete response rate with this combination in the neoadjuvant setting, in patients with advanced melanoma. He also reviews data from the CheckMate-067 study showing durable 6.5-year overall survival with first-line nivolumab plus ipilimumab in patients with advanced melanoma.
